Response to the Letter to the Editor "Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?" by Neoptolemos and Colleagues
- PMID: 29300712
- DOI: 10.1097/SLA.0000000000002028
Response to the Letter to the Editor "Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?" by Neoptolemos and Colleagues
Comment on
-
Locally Advanced Pancreatic Cancer: Neoadjuvant Therapy With Folfirinox Results in Resectability in 60% of the Patients.Ann Surg. 2016 Sep;264(3):457-63. doi: 10.1097/SLA.0000000000001850. Ann Surg. 2016. PMID: 27355262
-
Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders?Ann Surg. 2018 Feb;267(2):e35-e36. doi: 10.1097/SLA.0000000000002026. Ann Surg. 2018. PMID: 29300711 No abstract available.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
